Immunological and histopathological tumor responses to a novel neoadjuvant peptide vaccine (CYT001) targeting HSP70 and GPC3 antigens in patients with resectable HCC Masao Nakajima 1 , Shoichi Hazama 1 , Koji Tamada 1 , Keiko Udaka 2 , Shun Doi 3 , Michiie Sakamoto 4 , Akira Saito 5 , Shiro Akinaga 6 , Hiroto Matsui 1 , Yoshitaro Shindo 1 , Satoshi Matsukuma 1 , Yukio Tokumitsu 1 , Shinobu Tomochika 1 , Michihisa Iida 1 , Shin Yoshida 1 , Ryouichi Tsunedomi 1 , Yuki Nakagami 1 , Nobuaki Suzuki 1 , Shigeru Takeda 1 , Naoya Kato 7 , Hiroaki Nagano 1 1 Yamaguchi University, Ube, Yamaguchi, Japan; 2 Kochi University, Nangoku, Kochi, Japan; 3 CYTLIMIC Inc., Shinagawa, Tokyo, Japan; 4 Keio University, Shinjukuku, Tokyo, Japan; 5 Tokyo Medical University, Shinjukuku, Tokyo, Japan; 6 AccuRna Incorporation, Bunkyoku, Tokyo, Japan; 7 Chiba Yuniversity, Chuoku, Chiba, Japan Poster number: CT251